New Developments in Biological Markers in Prostate Cancer
The use of biological markers in the diagnosis and follow-up of patients with prostate cancer was pioneered by the work of Gutman et al. in 1936. In the intervening 50 years refinements in techniques and in the understanding of the physiological function of these normally occurring enzymes and proteins have enabled us to understand the potential and the problems associated with the use of these markers in clinical medicine. A review of biological markers in the prostate published previously by me (Pontes 1983) gave an extensive analysis of the value of specific and nonspecific markers in prostate cancer.
KeywordsAdenocarcinoma Perforation Phospho
Unable to display preview. Download preview PDF.
- Chan DW, Bruzek D, Rock R, Waldron C (1986) evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. Clin Chem 32: 1125Google Scholar
- Gutman E, Sproul E, Gutman A (1936) Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 28: 485Google Scholar
- Oesterling JE, Chan DW, Epstein JI, Kimball AW, Bruzek DJ, Rock RC, Brendler CB Walsh PC (1987) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139: 766Google Scholar
- Pontes JE, Jabalameli P, Montie J, Foemmel R, Howard PD; Boyett J (to be published), Disappearance rate of biological markers following radical prostatectomy —prognostic implications. Urology (to be published)Google Scholar